Your browser doesn't support javascript.
loading
Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination.
Davis, Chris; Logan, Nicola; Tyson, Grace; Orton, Richard; Harvey, William T; Perkins, Jonathan S; Mollett, Guy; Blacow, Rachel M; Peacock, Thomas P; Barclay, Wendy S; Cherepanov, Peter; Palmarini, Massimo; Murcia, Pablo R; Patel, Arvind H; Robertson, David L; Haughney, John; Thomson, Emma C; Willett, Brian J.
Affiliation
  • Davis C; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Logan N; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Tyson G; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Orton R; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Harvey WT; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Perkins JS; Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Mollett G; Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Blacow RM; Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Peacock TP; Department of Infectious Disease, Imperial College London, London, United Kingdom.
  • Barclay WS; Department of Infectious Disease, Imperial College London, London, United Kingdom.
  • Cherepanov P; The Francis Crick Institute, London, United Kingdom.
  • Palmarini M; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Murcia PR; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Patel AH; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Robertson DL; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Haughney J; Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
  • Thomson EC; MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
  • Willett BJ; Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.
PLoS Pathog ; 17(12): e1010022, 2021 12.
Article in En | MEDLINE | ID: mdl-34855916

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunization, Secondary / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Vaccine Efficacy / BNT162 Vaccine / Antibodies, Viral Limits: Humans Language: En Journal: PLoS Pathog Year: 2021 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunization, Secondary / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Vaccine Efficacy / BNT162 Vaccine / Antibodies, Viral Limits: Humans Language: En Journal: PLoS Pathog Year: 2021 Type: Article Affiliation country: United kingdom